1. Home
  2. CRGX vs SMBK Comparison

CRGX vs SMBK Comparison

Compare CRGX & SMBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRGX
  • SMBK
  • Stock Information
  • Founded
  • CRGX 2021
  • SMBK N/A
  • Country
  • CRGX United States
  • SMBK United States
  • Employees
  • CRGX N/A
  • SMBK N/A
  • Industry
  • CRGX
  • SMBK Major Banks
  • Sector
  • CRGX
  • SMBK Finance
  • Exchange
  • CRGX Nasdaq
  • SMBK Nasdaq
  • Market Cap
  • CRGX 190.0M
  • SMBK 553.9M
  • IPO Year
  • CRGX 2023
  • SMBK N/A
  • Fundamental
  • Price
  • CRGX $4.46
  • SMBK $36.08
  • Analyst Decision
  • CRGX Hold
  • SMBK Buy
  • Analyst Count
  • CRGX 7
  • SMBK 5
  • Target Price
  • CRGX $4.67
  • SMBK $34.40
  • AVG Volume (30 Days)
  • CRGX 502.9K
  • SMBK 69.7K
  • Earning Date
  • CRGX 08-11-2025
  • SMBK 07-21-2025
  • Dividend Yield
  • CRGX N/A
  • SMBK 0.89%
  • EPS Growth
  • CRGX N/A
  • SMBK 44.84
  • EPS
  • CRGX N/A
  • SMBK 2.26
  • Revenue
  • CRGX N/A
  • SMBK $171,664,000.00
  • Revenue This Year
  • CRGX $57.81
  • SMBK $20.95
  • Revenue Next Year
  • CRGX N/A
  • SMBK $9.48
  • P/E Ratio
  • CRGX N/A
  • SMBK $15.96
  • Revenue Growth
  • CRGX N/A
  • SMBK 16.34
  • 52 Week Low
  • CRGX $3.00
  • SMBK $23.09
  • 52 Week High
  • CRGX $25.45
  • SMBK $37.72
  • Technical
  • Relative Strength Index (RSI)
  • CRGX 57.89
  • SMBK 79.16
  • Support Level
  • CRGX $4.09
  • SMBK $33.63
  • Resistance Level
  • CRGX $4.51
  • SMBK $33.23
  • Average True Range (ATR)
  • CRGX 0.18
  • SMBK 0.73
  • MACD
  • CRGX 0.00
  • SMBK 0.37
  • Stochastic Oscillator
  • CRGX 77.18
  • SMBK 98.09

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.

About SMBK SmartFinancial Inc.

SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.

Share on Social Networks: